nlcq 1 hcl

NLCQ-1 is a novel weak DNA-intercalative bioreductive compound. NLCQ-1 exhibited a C50 of 44 microM. NLCQ-1 demonstrated significant hypoxic selectivity in several rodent (V79, EMT6, SCCVII) or human (A549, OVCAR-3) tumor cell lines. Its potency as a hypo

mTOR/HDAC-IN-1 HCl is a potent dual inhibitor of mTOR and HDAC with potential anti-inflammatory, anti-proliferative, autophagy and apoptosis-inducing effects for cancer research.

1-(3,4-dihydroxyphenyl)-2-(dimethylamino)ethan-1-one hydrochloride is a cholinergic agent that inhibits choline metabolism, which leads to increased levels of acetylcholine in the brain, which in turn enhances cognitive function and memory.

BMS 599626 2HCl (873837-23-1(HCl)) (AC480 dihydrochloride) is a selective inhibitor of HER1 and HER2 (IC50s: 20 nM and 30 nM), ~8-fold less potent to HER4, >100-fold to Lck, VEGFR2, c-Kit, MET, etc.

3-Piperidinyl(1-pyrrolidinyl)methanone hydrochloride can be used in the synthesis of piperidin-4-yl-urea derivatives which are MCH-R1 antagonists.

Compound PDK0269, as 5-HT3 receptor agonists(3–100 μM, pEC50 5.05±0.06), acutely increased XII (hypoglossal) burst frequency and regularity, and decreased bursts/episode . Phenylbiguanide produced a dose-related (10-500 microM) increase in the release of dopamine (280-2000%). When nomifensine (5 microM) was included in the Ringer solution, the effect of Compound PDK0269 on the release of dopamine was ameliorated or inhibited.

2-(7-Methoxy-1-naphthyl)ethylamine hydrochloride is the impurity of Agomelatine, an antidepressant.

GKI-1 HCl is a Greatwall (GWL) kinase inhibitor that inhibits hGWLFL and hGWL-KinDom.The inhibitory effect of GKI-1 HCl on ROCK1 is more significant.

1-(1-phenyltetrazol-5-yl)piperazine;hydrochloride (1-(1-phenyl-1H-1,2,3,4-tetrazol-5-yl)piperazine hydrochloride) is a chemical derivative of piperazine that has been used as a starting material for the synthesis of other compounds, such as anti-inflammatory agents. It modulates the activity of enzymes and proteins by binding to their active sites, and has been used in studies of enzyme inhibition and protein structure, as well as in drug metabolism.

FRAX486 HCL is a potent p21-activated kinase (PAK) inhibitor with IC50 values of 14, 33, 39 and 575 nM for PAK1, PAK2, PAK3 and PAK4 respectively.

OTUB1 USP8-IN-1 HCL is a potent dual inhibitor of OTUB1 and USP8 with potential antitumour activity, inhibiting both OTUB1 and USP8. OTUB1 USP8-IN-1 may be used in the study of leukaemia.

LY2606368 HCl is a selective ATP competitive inhibitor of checkpoint kinase 1 (IC50: 1.5nM in SW1990 cells).

Umibecestat is a beta-secretase inhibitor. CNP520 has a selectivity, pharmacodynamics, and distribution profile suitable for AD prevention studies.

ISQ-1 HCl is an isoquinolinone (IKur) blocker with possible atrial arrhythmia activity.

CIA-1 inhibits the nuclear receptor COUP-TFII, with IC50s ranging from 1.2 μM to 7.6 μM in prostate cancer cell lines.CIA-1 inhibits the growth of a variety of prostate cancer cell lines in vitro and inhibits COUP-TFII activity to regulate its target genes.CIA-1 in vivo exhibits tumor growth inhibitory effects in a mouse model of prostate cancer xenografts. inhibitory effect on tumor growth in a xenograft mouse model of prostate cancer in vivo.

ADRA1D receptor antagonist 1 HCl is an orally active, potent and selective α1D adrenergic receptor antagonist (Ki: 1.6 nM) with potential antiproliferative activity.